AU2005282624A1 - Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof - Google Patents

Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof Download PDF

Info

Publication number
AU2005282624A1
AU2005282624A1 AU2005282624A AU2005282624A AU2005282624A1 AU 2005282624 A1 AU2005282624 A1 AU 2005282624A1 AU 2005282624 A AU2005282624 A AU 2005282624A AU 2005282624 A AU2005282624 A AU 2005282624A AU 2005282624 A1 AU2005282624 A1 AU 2005282624A1
Authority
AU
Australia
Prior art keywords
receptor
nuclear receptor
degradation
nuclear
pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005282624A
Other languages
English (en)
Inventor
Charles C. Y. Shih
Ching-Yuan Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shih Charles C-Y
Original Assignee
Su Ching Yuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/045,181 external-priority patent/US20050209205A1/en
Application filed by Su Ching Yuan filed Critical Su Ching Yuan
Publication of AU2005282624A1 publication Critical patent/AU2005282624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005282624A 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof Abandoned AU2005282624A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60667804P 2004-09-02 2004-09-02
US60/606,678 2004-09-02
US11/045,181 2005-01-27
US11/045,181 US20050209205A1 (en) 2004-01-28 2005-01-27 Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
PCT/US2005/031447 WO2006029040A2 (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof

Publications (1)

Publication Number Publication Date
AU2005282624A1 true AU2005282624A1 (en) 2006-03-16

Family

ID=36036907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005282624A Abandoned AU2005282624A1 (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof

Country Status (6)

Country Link
EP (1) EP1804806A2 (de)
JP (1) JP2008540327A (de)
AU (1) AU2005282624A1 (de)
CA (1) CA2578159A1 (de)
MX (1) MX2007002583A (de)
WO (1) WO2006029040A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292569B2 (ja) * 2006-11-10 2013-09-18 国立大学法人名古屋大学 抗老化転写因子活性化剤及びその利用
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
WO2008085984A1 (en) 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
MX2010001125A (es) 2007-07-31 2010-09-30 Androscience Corp Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2770842B1 (fr) * 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
BRPI0407354A (pt) * 2003-02-11 2006-01-10 Warner Lambert Co Derivados de uréia e tiouréia

Also Published As

Publication number Publication date
MX2007002583A (es) 2007-09-14
WO2006029040A3 (en) 2008-12-04
CA2578159A1 (en) 2006-03-16
JP2008540327A (ja) 2008-11-20
EP1804806A2 (de) 2007-07-11
WO2006029040A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
US20060084704A1 (en) Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US9446127B2 (en) Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
Wang et al. Genistein suppresses psoriasis-related inflammation through a STAT3–NF-κB-dependent mechanism in keratinocytes
CA2636960C (en) Pharmaceutical composition comprising a specific inhibitor of hedgehog/smoothened signaling and a corticosteroid
JP5424923B2 (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
DE69731302T2 (de) Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
US20050209205A1 (en) Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
AU2005282624A1 (en) Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
Tian et al. Pentacyclic triterpene compounds from loquat leaves reduce skin inflammation and epidermal hyperplasia in psoriasis via inhibiting the Th17 cells
Guo et al. Magnolol may contribute to barrier function improvement on imiquimod‑induced psoriasis‑like dermatitis animal model via the downregulation of interleukin‑23
MX2008009442A (es) Uso de la minosina o un derivado de la misma, en el tratamiento de las manifestaciones cutaneas de la psoriasis y de los desordenes cutaneos relacionados con esta y una composicion cosmetica o farmaceutica que la comprende.
He et al. Amygdalin ameliorates alopecia areata on C3H/HeJ mice by inhibiting inflammation through JAK2/STAT3 pathway
Khafaji et al. Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice
Schoepe Investigations of in vitro Test Systems for the Detection of Glucocorticoid-induced Skin Atrophy as a Tool in Drug Discovery

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application